First Tracks Biotherapeutics, Inc. — Company profile
United States
Last price 45.08 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.89B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti‑CD122 antagonist that targets the shared beta subunit of the IL‑15 and IL‑2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2‑modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.
Details
| Name | First Tracks Biotherapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Founded | 2025 |
| Ceo | Daniel Faga |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US3371851029 |
| Cusip | 337185102 |
| Cik | 0002091349 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Daniel R. Faga | Chief Executive Officer, President and Director |
| Dr. Paul F. Lizzul M.D. | Chief Medical Officer |
| Ajim A. Tamboli C.F.A. | Chief Financial Officer |
Contact
| Address | 10770 Wateridge Circle, Suite 210, San Diego, California 92121, United States |
| Phone | 858 362 6295 |
| Website | https://www.firsttracksbio.com |